GLP-1 Weight Loss Therapy Candidates: Clinical Assessment

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Good candidates for GLP-1 weight loss therapy generally have a BMI of 30 or higher, or 27 or higher with weight-related health conditions like type 2 diabetes or hypertension. However, candidacy is more nuanced than a single metric. Medical history, medication interactions, lifestyle readiness, and individual metabolic factors all inform whether GLP-1 therapy aligns with your health goals and clinical needs.

Determining candidacy requires partnering with a qualified healthcare provider who can evaluate your complete health picture. PlexusDx supports this conversation by offering insights into genetic predispositions in GLP-1 and peptide response pathways, allowing providers to tailor discussions around medication selection and expected response patterns based on your individual biology.

Standard Clinical Eligibility Criteria

Clinical guidelines from the American Medical Association and endocrinology organizations define GLP-1 candidates primarily by BMI and comorbidity status. Adults with BMI 30 or greater, or BMI 27 or greater with at least one weight-related condition, are considered candidates for pharmacological weight management. These thresholds reflect evidence that GLP-1 medications reduce cardiovascular risk and weight significantly in these populations.

Candidacy also considers previous weight loss attempts, metabolic health markers, and medication history. Providers assess whether GLP-1 aligns with your overall treatment plan, particularly if you take other medications or have conditions affecting medication metabolism. Age, kidney function, and thyroid health are additional factors evaluated during candidate screening.

Key Medical and Lifestyle Factors That Influence Candidacy

Beyond BMI and comorbidities, several clinical and behavioral factors determine whether GLP-1 therapy is appropriate and likely to succeed. Understanding these factors helps you and your provider make an informed decision about whether treatment fits your current health status and readiness level.

Factor	Clinical Relevance
Thyroid Cancer History	GLP-1 contraindicated due to medullary thyroid cancer risk; requires alternative weight loss strategies.
Kidney Function (eGFR)	Dose adjustment may be needed if eGFR 15–30; not recommended if eGFR <15 without specialist guidance.
Gastrointestinal Surgery or Disorder	Conditions like gastroparesis may reduce GLP-1 efficacy or increase adverse effects; requires careful evaluation.
Medication Interactions	GLP-1 may affect insulin or sulfonylurea dosing; concurrent medications for cardiovascular or metabolic conditions require monitoring.
Pregnancy Status or Plans	GLP-1 not recommended during pregnancy; requires discussion about discontinuation timing if conception planned.
Pancreatitis History	Personal or family history of pancreatitis increases monitoring needs; not an absolute contraindication but requires specialist input.
Dehydration Risk or Diuretic Use	GLP-1-induced nausea may increase dehydration; higher risk in certain patient populations or with concurrent medications.
Treatment Adherence Readiness	Requires consistent medication administration; patient motivation and access to refills influence success likelihood.

How Genetic Predispositions May Inform Your GLP-1 Readiness

Emerging evidence suggests that variants in GLP-1 receptor pathways, GIPR signaling, and metabolic regulatory genes may influence individual response patterns to GLP-1 therapy. While genetic predisposition is not a definitive predictor of medication success, it may provide context for expected response trajectory, side effect profile, and dose requirements when reviewed with a qualified provider.

Genetic insights can support more informed conversations with your healthcare team about medication selection, monitoring strategy, and realistic outcome expectations. For example, certain genetic variants in GLP1R and GIPR pathways may correlate with stronger satiety signaling or metabolic response, potentially influencing which compounded formulation or protocol your provider recommends. This personalization approach complements, rather than replaces, clinical evaluation.

Safety Considerations and Contraindications

Absolute contraindications include personal or family history of medullary thyroid carcinoma, severe pancreatic disease, or uncontrolled diabetic retinopathy in some cases. Relative contraindications—conditions requiring closer monitoring or specialist input—include significant kidney impairment, active gastrointestinal disease, recent bariatric surgery, or concurrent use of certain medications that affect satiety or glucose metabolism.

Your provider will assess whether GLP-1 therapy is safe and appropriate by reviewing your complete medical history, current medications, and baseline lab values. Honest disclosure of all health conditions, surgeries, and family medical history is essential for safe candidacy determination. If you have complex medical needs, a specialist evaluation before starting GLP-1 can clarify readiness and help prevent adverse interactions.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test reveals predispositions in key GLP-1 and peptide response pathways, including variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313). These variants may help provide context for your individual metabolic profile and potential response patterns, supporting a more personalized conversation with your healthcare provider about GLP-1 candidacy and medication selection.

The genetic test specifically identifies predispositions in peptide signaling pathways—not exact medication response or guaranteed outcomes. For instance, certain GLP1R variants correlate with baseline GLP-1 receptor expression patterns, which may influence satiety response or dose titration strategy. However, genetics is one piece of the candidacy puzzle; clinical evaluation, comorbidities, and medication history are equally important in determining whether GLP-1 therapy is right for you.

When PlexusDx genetic insights are reviewed alongside your provider's clinical assessment, you gain a more complete picture of your candidacy. Your provider can discuss how your genetic predispositions may inform expected response timelines, potential side effect tolerability, and whether a specific compounded formulation or protocol aligns with your biology. This data-driven approach supports more confident, personalized treatment planning.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.